Contribution Agreements in the Biotechnology Industry

45 Contracts & Agreements

Browse by Company

ACADIA PHARMACEUTICALS INC (2 contracts)
AgeX Therapeutics, Inc. (1)
Allogene Therapeutics, Inc. (3)
Aptevo Therapeutics Inc. (1)
BioXcel Therapeutics, Inc. (1)
Capstone Therapeutics Corp. (1)
Cellular Biomedicine Group, Inc. (1)
Centessa Pharmaceuticals Ltd (10)
Eliem Therapeutics, Inc. (1)
Exelixis (2)
Gene Biotherapeutics, Inc. (1)
GERON CORP (1)
HedgePath Pharmaceuticals, Inc. (1)
Homology Medicines, Inc. (1)
Medovex Corp. (2)
Ohr Pharmaceutical Inc (1)
OncBioMune Pharmaceuticals, Inc (1)
Poseida Therapeutics, Inc. (1)
SELLAS Life Sciences Group, Inc. (7)
Sorrento Therapeutics, Inc. (4)
VBI Vaccines Inc (2)

Recent Contracts

Asset Contribution Agreement dated March 26, 2024 between AgeX Therapeutics, Inc. and UniverXome Bioengineering, Inc (AgeX Therapeutics, Inc., Filed With SEC on April 1, 2024)
Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Allogene Therapeutics, Inc., Filed With SEC on November 2, 2023)
Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex... (Sorrento Therapeutics, Inc., Filed With SEC on September 14, 2022)
Amendment to the Contribution Agreement, signed March 28, 2022, by and among VBI Vaccines, Inc., Variation Biotechnologies, Inc. and Her Majesty The Queen in Right of Canada as... (VBI Vaccines Inc, Filed With SEC on May 9, 2022)
Contribution Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Homology Medicines, Inc., Filed With SEC on March 23, 2022)
Asset Contribution Agreement, dated February 4, 2019, by and between the Registrant and Carnot, LLC (Eliem Therapeutics, Inc., Filed With SEC on July 16, 2021)
Contribution Agreement, dated December 31, 2020 (as amended), by and between PearlRiver Bio GmbH, United Medicines Biopharma Limited, and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution Agreement, dated January 23, 2020, by and between Pega-One, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Z Factor Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Orexia Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Morphogen-IX Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between LockBody Therapeutics Ltd, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Janpix Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Inexia Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between Capella Bioscience LTD, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution agreement, dated January 23, 2021, by and between ApcinteX Limited, United Medicines Biopharma Limited and the other parties thereto (Centessa Pharmaceuticals Ltd, Filed With SEC on April 21, 2021)
Contribution Agreement dated April 2, 2021 (Medovex Corp., Filed With SEC on April 8, 2021)
Contribution Agreement, dated September 16, 2020, by and among VBI Vaccines, Inc., Variation Biotechnologies, Inc. and Her Majesty The Queen in Right of Canada as Represented by... (VBI Vaccines Inc, Filed With SEC on November 2, 2020)
Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March... (OncBioMune Pharmaceuticals, Inc, Filed With SEC on February 21, 2019)
Asset Contribution Agreement, by and between the Registrant and Transposagen Biopharmaceuticals, Inc., dated February 9, 2015 (Poseida Therapeutics, Inc., Filed With SEC on January 4, 2019)
Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Allogene Therapeutics, Inc., Filed With SEC on October 2, 2018)
Asset Contribution Agreement, dated April 2, 2018, by and between the Registrant and Pfizer Inc (Allogene Therapeutics, Inc., Filed With SEC on September 14, 2018)
Amended and Restated Asset Contribution Agreement, effective November 7, 2017, by and between BioXcel Corporation and BioXcel Therapeutics, Inc (BioXcel Therapeutics, Inc., Filed With SEC on February 12, 2018)
Amendment No. 2 to Contribution Agreement, dated as of August 10, 2017, by and among Sorrento Therapeutics, Inc., TNK Therapeutics, Inc. and Celularity, Inc (Sorrento Therapeutics, Inc., Filed With SEC on November 9, 2017)
AMENDMENT NO. 1 TO CONTRIBUTION AGREEMENT (Sorrento Therapeutics, Inc., Filed With SEC on August 9, 2017)
CONTRIBUTION AGREEMENT by and among CELULARITY, INC., TNK THERAPEUTICS, INC. and SORRENTO THERAPEUTICS, INC. Dated: June 12, 2017 (Sorrento Therapeutics, Inc., Filed With SEC on August 9, 2017)
CONTRIBUTION AGREEMENT (Aptevo Therapeutics Inc., Filed With SEC on August 2, 2016)
CONTRIBUTION AGREEMENT BETWEEN TAXUS CARDIUM PHARMACEUTICALS GROUP & ANGIONETICS INC. (Gene Biotherapeutics, Inc., Filed With SEC on July 11, 2016)
CONTRIBUTION AND ROYALTY AGREEMENT (Medovex Corp., Filed With SEC on September 8, 2014)
Contribution Agreement (Ohr Pharmaceutical Inc, Filed With SEC on May 16, 2014)
CONTRIBUTION AGREEMENT (HedgePath Pharmaceuticals, Inc., Filed With SEC on August 16, 2013)
CONTRIBUTION AGREEMENT (Cellular Biomedicine Group, Inc., Filed With SEC on February 12, 2013)
CONTRIBUTION AGREEMENT (Capstone Therapeutics Corp., Filed With SEC on August 10, 2012)
CONTRIBUTION AGREEMENT (SELLAS Life Sciences Group, Inc., Filed With SEC on September 26, 2011)
VOLUME SUBMITTER DEFINED CONTRIBUTION PLAN (PROFIT SHARING/401(K) PLAN) (Exelixis, Filed With SEC on March 10, 2010)
DEFINED CONTRIBUTION PLAN FIDELITY BASIC PLAN DOCUMENT NO. 14 (Exelixis, Filed With SEC on March 10, 2010)
VOLUME SUBMITTER DEFINED CONTRIBUTION PLAN (PROFIT SHARING/401(K) PLAN) (ACADIA PHARMACEUTICALS INC, Filed With SEC on March 9, 2010)
VOLUME SUBMITTER DEFINED CONTRIBUTION PLAN FIDELITYBASIC PLAN DOCUMENT NO. 14 Acadia Pharmaceuticals 401(k) Plan and Trust (ACADIA PHARMACEUTICALS INC, Filed With SEC on March 9, 2010)
CONTRIBUTION AGREEMENT (GERON CORP, Filed With SEC on August 12, 2008)
EX-4.7 - Amendment to Exhibit A to Contribution Agreement dated July 28, 2008 (SELLAS Life Sciences Group, Inc., Filed With SEC on August 4, 2008)